Расширенный поиск

Форадил в терапии ХОБЛ: результаты клинических исследований

Полный текст:

Об авторах

Е. Н. Калманова
НИИ пульмонологии Минздрава РФ


З. Р. Айсанов
НИИ пульмонологии Минздрава РФ


Список литературы

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 1995; 152: S77-S120.

2. Appleton S., Smith B., Veale A., Bara A. Long-acting P2-agonists for COPD (Cochrane review). In: The Cochrane Library. Oxford, UK: Update Software; 2000; issue 3. Available from

3. Benhamou D., Muir J.-F., Leclerc V. et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer®) with salbutamol (Ventodisk™). Respir. Med. 2001; 95: 817-821.

4. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.): S1-S28.

5. Cazzola M ., Santangelo G., Piccolo A. et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 1994; 7: 103-107.

6. Cazzola M., Matera M.G., Santangelo G. et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir. Med. 1995; 89: 357-362.

7. Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415.

8. Cazzola M ., DiPerna F., Califano C. et al. Formoterol Turbuhaler (F) versus salmeterol Diskus (S) in patients with partially reversible stable COPD [abstr]. Am. J. Respir. Crit. Care Med. 1999; 159: A798.

9. Cazzola M., Centanni S., Regorda C. et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm. Pharmacol. Ther. 2001; 14: 41-45.

10. Cazzola M ., DiPerna F., D'Amato M . et al. Formoterol Turbuhaler® for as-needed therapy in patients with mild acute exacerbations of COPD. Respir. Med. 2001; 95: 917-921.

11. Celik G., Kayacan O., Beder S. et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434-439.

12. Cordina M ., Cacciottolo J.M., Jones C.H., Saliba N. Healthrelated quality of life (HRQL) and the use of formoterol in patients with COPD [abstr]. Eur. Respir. J. 2001; 18 (suppl.33): 55s.

13. Dahl R., Kristufek P., Greefhorst A.P.M . et al. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD [abstr]. Ibid. 2000; 16 (suppl.31): 51s.

14. Dahl R., Greefhorst L.A.P.M., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784.

15. DiBartolio C.G., Gonzalez J.G., Ruggieri M .P. et al. Evaluation of the effectiveness and acceptability of Foradil®Aerolizer™ and Oxis Turbuhaler® in asthmatics. In: Program and abstracts of the 96th International conference of the American Thoracic Society. Toronto, Ontario; 2000. Session A21.

16. D'U rzo A.D., De Salvo M.C., Ramirez A. et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119 (5): 1347-1356.

17. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.

18. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2003.

19. Guyatt G., Townsend M ., Keller J. et al. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir. Med. 1991; 85 (suppl.B): 17-21.

20. Hacki M.A., Hitiz G.W., Medici T.C. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin. Drug Invest. 1997; 14: 165-174.

21. Johnson M ., Rennard S. Alternative mechanisms of long-acting (32-adrenergic agonists in COPD. Chest 2001; 120: 258-270.

22. Kalmanova E.N., Stulova O.Y., Aisanov Z.R. Influence of longacting p2-agonist and sustained-release theophylline on maximal exercise capacity and endurance time in asthmatic patients. Eur. Respir. J. 2003; 22 (suppl.35) (in press).

23. Kottakis J., Cioppa G.D., Creemers J. et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. 2002; 9: 107-115.

24. Linden A., Bergendal A., Gilman A. et al. Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.

25. Lotvall J., Mellen A., Arvidsson P. et al. Similar bronchodilation with formoteroldelivered by aerolizer or turbuhaler. Can. Respir. J. 1999; 6: 412-416.

26. Maesen B.L.P., Westermann C.J.J., Duurkens V.A.M., van den Bosch J.M .M . Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 1103-1108.

27. Maesen F.P.V., Costongs R., Smeets S.J. et al. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101: 1376-1381.

28. Mahler D., Tomlinson D., Olmstead E. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.

29. McKay S.E., Howie C.A., Thomson A.H. et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227.

30. Naline E., Zhang Y., Qian Y. et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur. Respir. J. 1994; 7: 914-920.

31. O'Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled (Vagonists in asthma. N. Engl. J. Med. 1992; 327: 1204-1208.

32. Pauwels R.A., Buist S.A., Calverley P.M.A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD). Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.

33. Redelmeier D., Goldstein R., Minutes S. et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996; 109: 1163-1168.

34. Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Ibid. 2002; 121: 1058-1069.

35. Sichletidis L., Kottakis J., Marcou S. et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int. J. Clin. Pract. 1999; 53: 185-188.

36. Ziment I. Pharmacological therapy of obstructive airway disease. Clin. Chest Med. 1990; 11: 461-486.


Для цитирования:

Калманова Е.Н., Айсанов З.Р. Форадил в терапии ХОБЛ: результаты клинических исследований. Пульмонология. 2003;(5):115-122.

For citation:

Kalmanova E.N., Aisanov Z.R. Foradil in therapy of COPD: results of clinical trials. PULMONOLOGIYA. 2003;(5):115-122. (In Russ.)

Просмотров: 22

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)